An overview of drugs for the treatment of Mycobacterium kansasii pulmonary disease

Srivastava, Shashikant; Pasipanodya, Jotam G.; Heysell, Scott K; Boorgula, Gunavanthi D.; Gumbo, Tawanda; McShane, Pamela J.; Philley, Julie V.

doi:10.1016/j.jgar.2021.12.010

Cited by 1 publication

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two studies reported on MIC distribution of SGM species in 7H9. 36 , 49 In one study, the bedaquiline MIC distributions of M. avium and M. intracellulare in 7H9 were mostly in the ranges 0.003–1.0 and 0.003–0.5 mg/L, respectively, with the MIC modes being 0.015 and 0.007 mg/L, respectively (Figure S3 ). The majority of M. avium (98/124; 79.0%) and M. intracellulare (37/42; 88.1%) isolates had a bedaquiline MIC of <0.03 mg/L.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Bedaquiline for treatment of non-tuberculous mycobacteria (NTM): a systematic review and meta-analysis

Omar,

Whitfield,

Nolan

et al. 2023

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

Background Non-tuberculous mycobacteria (NTM) infections are increasing in incidence and associated mortality. NTM are naturally resistant to a variety of antibiotics, complicating treatment. We conducted a literature assessment on the efficacy of bedaquiline in treating NTM species in vitro and in vivo (animal models and humans); meta-analyses were performed where possible. Method Four databases were searched using specific terms. Publications were included according to predefined criteria. Bedaquiline’s impact on NTM in vitro, MICs and epidemiological cut-off (ECOFF) values were evaluated. A meta-analysis of bedaquiline efficacy against NTM infections in animal models was performed. Culture conversion, cure and/or relapse-free cure were used to evaluate the efficacy of bedaquiline in treating NTM infection in humans. Results Fifty studies met the inclusion criteria: 33 assessed bedaquiline’s impact on NTM in vitro, 9 in animal models and 8 in humans. Three studies assessed bedaquiline’s efficacy both in vitro and in vivo. Due to data paucity, an ECOFF value of 0.5 mg/mL was estimated for Mycobacterium abscessus only. Meta-analysis of animal studies showed a 1.86× reduction in bacterial load in bedaquiline-treated versus no treatment within 30 days. In humans, bedaquiline-including regimens were effective in treating NTM extrapulmonary infection but not pulmonary infection. Conclusions Bedaquiline demonstrated strong antibacterial activity against various NTM species and is a promising drug to treat NTM infections. However, data on the genomic mutations associated with bedaquiline resistance were scarce, preventing statistical analyses for most mutations and NTM species. Further studies are urgently needed to better inform treatment strategies.

show abstract

Section: Resultsmentioning

confidence: 99%

“…The other study reported on bedaquiline MIC distribution of only 20 isolates of M. kanasasii , in which most isolates ( n = 20) had bedaquiline MIC of 0.03 mg/L and only 2 isolates were resistant to bedaquiline with MIC of 2 mg/L (Figure S3 ). 49 …”

Section: Resultsmentioning

confidence: 99%